Sagimet Biosciences officer proposes $147K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Sagimet Biosciences Inc. director and officer George Kemble reported a proposed sale of 18,844 common shares, with an aggregate market value of $147,360.08. The approximate sale date is July 20, 2026, and Morgan Stanley Smith Barney LLC is listed as broker. The shares are listed as restricted stock units acquired from the issuer on July 18, 2026. The form lists August 21, 2025 as the date of plan adoption or instruction, if relying on Rule 10b5-1.
Key Figures
Key Terms
Restricted Stock Units financial
Rule 10b5-1 regulatory
Aggregate Market Value financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
Which broker is listed for George Kemble's proposed SGMT sale?
What Rule 10b5-1 date is listed for George Kemble's proposed SGMT sale?
AI-generated analysis. How Rhea-AI works. Not financial advice.